drugset
drugset / Trial / NCT04465864

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

NCT04465864 ↗

Phase 4 Completed 40 enrolled Wolstan and Goldberg Eye Associates
RandomizedParallel-groupSingle-blindTreatment

Summary

Randomized, controlled treatment with an intracanalicular dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHTN)

Timeline

Start
2020-02-10
Primary completion
2020-12-31
Completion
2021-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other

Indications

cataract open-angle glaucoma